Influence of interferon on the functional and structural changes of central nervous system from the viewpoints of aging and gender

从衰老和性别角度观察干扰素对中枢神经系统功能和结构变化的影响

• 批准号: 21590857
• 负责人: SUZUKI Kazuyuki
• 金额: $ 2.83万
• 依托单位: Iwate Medical University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2009
• 资助国家: 日本
• 起止时间: 2009 至 2011
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-21590857/
• 关键词: ウイルス; インターフェロン; 薬剤反応; 細胞・組織; シグナル伝達; 肝炎ウイルス; 薬物反応; 細胞・祖時期

Clinical study : Among the patients with chronic hepatitis C treated with PEG-IFN/Ribavirin, the neuropsychiatric symptoms(insomnia, poor mood and depressive state) appeared more commonly in males than females. The age and sex were not associated with the sustained viral response. The self-rating depression scale(SDS) points worsened during the treatment and PDG-PET scan revealed a tendency of decreased cerebral glucose metabolism(CMRglu) in the entire brain regions, However, SDS points and CMRglu returned to pre-treatment values after the therapy. However, no relationship was seen between two parameters. Experimental study : The expressions of both IFN receptors(IFN-R1 and R2) were detectable in the cultured human astrocytes. A physiologically-relevant concentrations of IFNα2a and α2b(i. e., 2 IU/ml) both inhibited the expression of the INF receptors and significantly decreased the proliferation of human astrocytes. In contrast, IFN-β did not affect astrocyte proliferation. IFN-α treatment inhibited the Glut-1 expression, resulting in deceased glucose consumption. These effects were associated, in part, with the alterations in cytokines such as interleukin-8.

临床研究：在PEG-IFN/利巴韦林治疗的慢性丙型肝炎患者中，男性出现的神经精神症状（失眠、情绪差、抑郁状态）多于女性。年龄和性别与持续的病毒反应无关。自评抑郁量表（SDS）积分在治疗期间加重，PDG-PET扫描显示全脑区脑糖代谢（CMRglu）有下降趋势，但治疗后SDS积分和CMRglu恢复到治疗前值。然而，两个参数之间没有关系。实验研究：在培养的人星形胶质细胞中检测到IFN受体（IFN- r1和R2）的表达。ifn - α2a和α2b的生理相关浓度(i。（2 IU/ml）均抑制了INF受体的表达，并显著降低了人星形胶质细胞的增殖。相反，IFN-β不影响星形胶质细胞增殖。IFN-α抑制Glut-1表达，导致葡萄糖消耗减少。这些影响在一定程度上与白细胞介素-8等细胞因子的变化有关。

项目成果

私の処方潜在性肝性脳症の治療

我的亚临床肝性脑病治疗处方

• 发表时间: 2009
• 期刊: Modern Physician
• 作者: Iwasaki Y;Shiratori H;Hige S;Nishiguchi S;Takagi H;Onji M;Yoshida H;Izumi N;Kohgo Y;Yamamoto K;Sato N;Shibuya A;Saito H;Sata M;Suzuki K;Kaneko S;Moriyama M;Omata M;鈴木一幸
• 通讯作者: 鈴木一幸

私の処方 潜在性肝性脳症の治療

我的治疗亚临床肝性脑病的处方

• 发表时间: 2009
• 期刊: Modern Physician 29
• 作者: Kawamura E;Enomoto M;Kotani K;Hagihara A;Fujii H;Kobayashi S;Iwai S;Morikawa H;Kawabe J;Tominaga K;Tamori A;Shiomi S;Kawada N;鈴木一幸
• 通讯作者: 鈴木一幸

肝性脳症の治療のup-data(総説)

肝性脑病治疗的最新数据（综述）

• 发表时间: 2010
• 期刊: 日本消化器病学会雑誌
• 作者: 宮坂昭生;鈴木一幸;鈴木一幸;鈴木一幸
• 通讯作者: 鈴木一幸

Interferon-α inhibits the proliferation of human astrocyte and decrease the expression of glucose transporter Glut-1

干扰素-α 抑制人星形胶质细胞增殖并降低葡萄糖转运蛋白 Glut-1 的表达

• 发表时间: 2011
• 作者: Takikawa Y;Suzuki K;et al.(5名中5番目)
• 通讯作者: et al.(5名中5番目)

Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon a-2b for advanced hepatocellular carcinoma with portal venous invasion

• DOI: 10.1002/cncr.26648
• 发表时间: 2012-07-01
• 期刊: CANCER
• 影响因子: 6.2
• 作者: Kasai, Kazuhiro;Ushio, Akira;Suzuki, Kazuyuki
• 通讯作者: Suzuki, Kazuyuki